News

The medical director of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children's discussed data on ARU-1801 presented at ASH 2021.

The SURPASS-2 trial will run parallel to the ongoing SURPASS trial.

The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod cell therapy in solid tumors.

Investigators from IRCCS San Raffaele analyzed results from a phase 1/2 study on atidarsagene autotemcel.

Dolores Schendel, PhD, chief executive and chief scientific officer, Medigene, discussed MDG1011 and Medigene’s future research and targets.

The BASECAMP-1 study is identifying patients for future use of Tmod CAR T-cell therapies.

The T-cell therapy targets 6 tumor-associated antigens that are highly expressed in pancreatic cancer.

The associate professor from Fred Hutchinson Cancer Research Center discussed the methods utilized in an ongoing phase 1/2 trial evaluating MB-106.

Positive data from a phase 1 trial were presented at the 2021 ASCO meeting.

Review top news and interview highlights from the week ending January 21, 2022.

The FDA and Gamida Cell have reached a consensus on the comparability of omidubicel manufactured at different sites.

Data from the phase 2 QUILT-88 study were presented at the 2022 ASCO GI symposium.

Carisma Therapeutics and Moderna are also collaborating to develop CAR-M cell therapies.

Further details on the KEYNOTE-B79 trial were presented at the 2022 ASCO GI Symposium.

Greg Kunst, chief executive officer, Aurion Biotech, discussed the potential of cell therapy in treating people with corneal endothelial disease around the world.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in gene and cell therapies.

The phase 1/2 ARYA-2 trial will be run in parallel with the similar phase 1/2 ARYA-1 and ARYA-3 trials.

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from the CARTITUDE-1 study presented at ASH 2021.

Eli-cel remains on clinical hold in cerebral adrenoleukodystrophy after a report of persistent anemia.

The designation follows the approval of its IND application for the natural killer cell therapy in November 2021.

The first patient with Fabry disease dosed with FLT190 2 years ago continues to have elevated, sustained α-Gal A.

The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod technology in solid tumors.

The ASCENT trial is kicking off while the ATMOSPHERE trial continues to screen patients with wet AMD.

Experts discuss recommendations to increase the uptake of CAR T-cell therapies into clinical practice and relapsed/refractory diffuse large B-cell lymphoma.

The professor from University of Texas MD Anderson Cancer Center discussed the FDA approval of lisocabtagene maraleucel.

Cedrik Britten, MD, chief medical officer, Immatics, discussed the advantages of IMA203 over other cell therapies.

Details on the phase 1/2 CEDAR trial were presented at the 2021 ASH meeting.

Review top news and interview highlights from the week ending January 14, 2022.